Everything this week has pointed toward a single idea, that sarcoma outcomes track with how often a place actually treats sarcoma, and in 2026 a large U.S. study finally put a firm number on it. Hospitals treating higher volumes of sarcoma reported five-year overall survival of 64.8%, compared with 60.0% at lower-volume hospitals, a gap of nearly five percentage points that is enormous for a single, modifiable factor.
What makes it striking is that the factor is not a new molecule or a genetic breakthrough but simple concentration, the effect of teams, pathologists, and surgeons who handle sarcoma frequently working in places built around it. The study even identified thresholds for what counts as high volume, which underscores that this is a measurable property of a hospital rather than a vague impression of quality. And because it is the American echo of the earlier French reference-center findings, the agreement across two very different health systems becomes the real point: when independent datasets on opposite sides of the ocean keep landing on the same conclusion, it stops being a quirk and starts being a rule.
For patients, that rule turns an abstract preference into a concrete question you can actually ask out loud. Not “are you a good hospital,” which no one will answer no to, but “how many sarcomas like mine do you treat in a year, and is there a higher-volume sarcoma center I should be seen at?” The answer tells you something real about your odds.
None of this means every patient must uproot their life for every step of care, since a great deal of treatment can be coordinated closer to home once a specialist center has set the plan. But the pivotal decisions, the diagnosis, the surgical strategy, the pathology, belong where sarcoma is seen constantly, and the question of how many cases a place sees each year is, for a cancer this rare, one of the most important numbers in your care.